<DOC>
	<DOC>NCT02000830</DOC>
	<brief_summary>The objectives of this follow up study are to evaluate the long-term effects of stannsoporfin (Stanate) on the health, growth, and development of patients who received a single dose of stannsoporfin with PT used to treat hyperbilirubinemia compared with patients in the control (placebo plus PT) group in clinical trial 64,185-204.</brief_summary>
	<brief_title>Follow up Study of Patients Having Participated in Clinical Trial 64,185-204</brief_title>
	<detailed_description>Outcomes will be based on the following variables: Reported AEs and SAEs Hearing assessments Developmental assessments</detailed_description>
	<mesh_term>Tin mesoporphyrin</mesh_term>
	<criteria>Patients who received IMP (stannsoporfin or placebo) in clinical trial 64,185204 Parents or guardians have given written informed consent to participate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>52 Months</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stannsoporfin</keyword>
</DOC>